Core Viewpoint - The stock price of Ailis (688578) has shown fluctuations over the past week, with a slight increase observed recently, indicating a mixed sentiment in the market [1]. Stock Performance - As of February 13, 2026, the latest stock price is 96.95 yuan, reflecting a minor increase of 0.05% from the previous day [1]. - Over the past five days, the stock has experienced a cumulative decline of 0.05%, although it recorded consecutive gains on February 11 and 12 [1]. Capital Flow - On February 9, there was a net outflow of main funds amounting to 6.4029 million yuan, followed by a further outflow of 15.8260 million yuan on February 11 [1]. - However, on the morning of February 13, main funds turned to a net inflow of approximately 3.3 million yuan, suggesting a short-term recovery in capital sentiment [1]. Market Context - The stock price has been fluctuating within the range of 95 to 98 yuan, with trading volume remaining relatively low [1]. - The overall performance has been influenced by a slight adjustment in the broader pharmaceutical sector [1].

盐酸普萘洛尔主要用于(i)作为二级预防，降低心肌梗死死亡率;(ii)高血压;(iii)劳力型心绞痛;及(iv)控制室 上性快速心律失常及室性心律失常。 石四药集团(02005)发布公告，本集团的盐酸普萘洛尔已获中国国家药品监督管理局批准登记成为在上 市制剂使用的原料药。 ...

Group 1 - Huangshan Capsule's stock price has increased for seven consecutive days, with a cumulative rise of 5.98%, but experienced a decline of 2.59% on February 12 [1] - The stock price fluctuated significantly over the past seven trading days, with a closing price of 8.37 yuan on February 6, peaking at 8.53 yuan on February 11, and dropping to 8.29 yuan on February 12, resulting in a price range fluctuation of 2.99% [2] - The main business of Huangshan Capsule includes gelatin hollow capsules and enteric-coated gelatin hollow capsules, indicating a stable revenue structure [1] Group 2 - Institutional interest in Huangshan Capsule is relatively low, with a fund holding ratio of only 0.03% and a low ranking in industry research frequency, with ratings being neutral [3] - The earnings forecast for 2024 indicates an expected earnings per share of 0.16 yuan, with a projected net profit decline of 24.07%, suggesting limited improvement in fundamentals [3]

公司已于2026年1月完成乐康制药100%股权转让(价格6250万元)，并于2025年12月完成罗欣安若维他 20%股权转让。这些处置有助于减少非经营性损益拖累，后续亏损影响将逐步消除。 经济观察网罗欣药业（002793）近期发布2025年业绩预告，预计归母净利润亏损显著收窄，同时核心创 新药替戈拉生片商业化放量，研发管线取得关键进展。 业绩经营情况 公司于2026年1月30日发布业绩预告，预计2025年归母净利润亏损收窄至-2.5亿元至-3.4亿元，较2024年 同期亏损(-9.65亿元)显著改善。扣非净利润预计为-2.6亿元至-3.5亿元。后续需关注审计机构的最终审计 结果，正式年报预计在2026年4月前披露。 业务进展情况 国家1类创新药替戈拉生片(泰欣赞)的三大适应症已全面纳入2025年版国家医保目录，支付端障碍消 除。2025年上半年，该产品进院数量激增近2500家，销售量同比增长约140%。未来其销售规模效应和 运营效率的提升值得跟踪。 产品研发进展 公司重点研发的注射用LX22001目前已进入Ⅱ期临床试验阶段；普卡那肽片Ⅲ期临床研究报告已完成定 稿，正推进地产化落地。这些创新药进展可能影响公司长 ...

Belén Garijo 拥有西班牙国籍，曾在医院工作六年，之后投身制药行业。她先是在雅培的研发部门工 作，随后在赛诺菲工作了 15 年。2011 年加入默克集团，并于 2021 年成为首席执行官。 来源：市场资讯 （来源：求实药社） 2 月 12 日，赛诺菲宣布，董事会决定不再续聘 Paul Hudson CEO 的职务，其将在 2026 年 2 月 17 日正 式卸任。同时，董事会任命了 Belén Garijo 作为新任 CEO，将在 2026 年 4 月 29 日集团股东大会结束后 正式就职。 另外，在 2026 年 2 月 17 日至 4 月 29 日期间，执行副总裁 Olivier Charmeil 将在过渡期间担任临时首席 执行官。 文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中 立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自 行承担全部。 ...

鹽酸普萘洛爾主要用於 (i) 作為二級預防，降低心肌梗死死亡率；(ii) 高血壓；(iii) 勞力型心 絞痛；及(iv) 控制室上性快速心律失常及室性心律失常。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的鹽酸普萘洛爾已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原料藥。 周興揚 香港，二零二六年二月十三日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for Heng Rui Pharmaceutical (600276) and "Increase" for WuXi Biologics (603259) [46] Core Insights - The recent national drug procurement has been stable, with active participation from companies and continued benefits for patients [8][9] - The issuance of the "National Basic Drug Directory Management Measures" aims to enhance the management of essential medicines [10][11] - Heng Rui Pharmaceutical reported positive top-line results for its GLP-1/GIP dual receptor agonist, indicating significant weight loss in clinical trials [12] - The approval of Mu Feng Da® for the treatment of adult type 2 diabetes marks a significant development in the market [12] Industry News - The national drug procurement involved 316 commonly used drugs across 26 therapeutic areas, with a high participation rate from over 5,100 medical institutions and 1,091 companies [8][9] - The procurement process has been standardized, allowing companies to bid online once for nationwide sales, significantly reducing costs [9] - The management measures for the national basic drug directory have been revised to include legal policy bases and optimize the directory structure [10][11] Company Announcements - Innovent Biologics has entered a global strategic partnership with Eli Lilly to advance new drug development in oncology and immunology [26] - Kelun Pharmaceutical's TROP2 ADC has received approval for a fourth indication from the NMPA [27] - Heng Rui Pharmaceutical's drug has been included in the list of breakthrough therapy products, and its application for marketing approval has been accepted for priority review [28] - WuXi Biologics has forecasted a positive earnings outlook, expecting a revenue increase of approximately 16.7% [30] Market Review - The Shanghai Composite Index rose by 1.43%, while the Shenzhen Component Index increased by 2.37%, with the SW Pharmaceutical and Biotech Index up by 0.23% [36] - The industry’s price-to-earnings ratio (TTM) stands at 51.17, with a valuation premium of 259% compared to the CSI 300 [40] Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring performance recovery indicators [46]

Core Viewpoint - The stock price of Weixin Kang (卫信康) has shown a fluctuating trend over the past week, with a range of 0.27% and an amplitude of 2.14% [1] Group 1: Stock Performance - As of February 12, the closing price was 11.26 yuan, down 1.14% for the day, with a trading volume of 14.43 million yuan [1] - On February 11, the closing price was 11.39 yuan, reflecting a decrease of 0.35% [1] - Over the past five days, there has been a net outflow of 1.1653 million yuan in main funds, while on February 11, there was a net inflow of 115,100 yuan [1] Group 2: Recent Events - On February 9, 2026, a national drug procurement process was initiated, involving 316 commonly used drugs, which may impact the overall competitive landscape of the pharmaceutical industry until the end of 2028 [2] - Weixin Kang has no significant new events recently, but its calcium gluconate injection has passed the consistency evaluation for generic drugs, expected by December 2024 [2] Group 3: Financial Report Analysis - The third-quarter report for 2025 indicates that Weixin Kang's revenue for the first three quarters was 862 million yuan, a year-on-year decrease of 13.27% [3] - The net profit attributable to the parent company was 219 million yuan, down 9.90% year-on-year [3] Group 4: Institutional Perspectives - Institutions have set a comprehensive target price of 15.20 yuan for Weixin Kang, indicating a potential upside of approximately 34.99% from the latest price [4] - Current market sentiment is neutral, with low frequency of institutional research, while profit forecasts suggest a projected net profit growth of 25.93% for 2026 [4]

公开资料显示，LAE002(Afuresertib)是来凯医药开发的一种AKT强效抑制剂。由徐兵河院士牵头的 LAE002联合氟维司群，针对治疗HR+/HER2-局部晚期或转移性乳腺癌(LA/mBC)伴随 PIK3CA/AKT1/PTEN通路改变患者的III期临床试验AFFIRM-205正顺利推进，2025年12月已经完成III期 入组，目标于今年上半年公布顶线数据，并计划今年年中向中国国家药品监督管理局药品审评中心提交 新药上市申请。2025年11月，来凯医药与齐鲁制药签订了中国地区独家许可协议，加速商业化 LAE002。 来凯医药(02105)午前涨超5%，截至发稿，涨4.82%，报12.82港元，成交额1253.32万港元。 消息面上，国际科学期刊《自然-通讯》(Nature Communications)2月6日在线发表了中国工程院院士、中 国医学科学院肿瘤医院徐兵河教授领衔的《Afuresertib联合氟维司群治疗经治HR+HER2-晚期乳腺癌： 一项Ib期试验》，表明该联合治疗方案在晚期乳腺癌患者中显示出令人鼓舞的抗肿瘤活性和良好的安全 性特征。 ...

智通财经APP获悉，来凯医药(02105)午前涨超5%，截至发稿，涨4.82%，报12.82港元，成交额1253.32 万港元。 公开资料显示，LAE002(Afuresertib)是来凯医药开发的一种AKT强效抑制剂。由徐兵河院士牵头的 LAE002联合氟维司群，针对治疗HR+/HER2-局部晚期或转移性乳腺癌（LA/mBC）伴随 PIK3CA/AKT1/PTEN通路改变患者的III期临床试验AFFIRM-205正顺利推进，2025年12月已经完成III期 入组，目标于今年上半年公布顶线数据，并计划今年年中向中国国家药品监督管理局药品审评中心提交 新药上市申请。2025年11月，来凯医药与齐鲁制药签订了中国地区独家许可协议，加速商业化 LAE002。 消息面上，国际科学期刊《自然-通讯》（Nature Communications）2月6日在线发表了中国工程院院 士、中国医学科学院肿瘤医院徐兵河教授领衔的《Afuresertib联合氟维司群治疗经治HR+HER2-晚期乳 腺癌：一项Ib期试验》，表明该联合治疗方案在晚期乳腺癌患者中显示出令人鼓舞的抗肿瘤活性和良好 的安全性特征。 ...